What question did this study set out to answer?

This study aims to explore the protective mechanisms of astragaloside IV against acetaminophen-induced liver injury.

Astragaloside IV Ameliorates Acetaminophen‐Induced Liver Injury via Targeting the PCK1/PPARG/RXRA‐Mediated PPAR Signaling Pathway

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates astragaloside IV's protective effects on liver injury in mice, indicating potential therapeutic use.

This study aims to explore the protective mechanisms of astragaloside IV against acetaminophen-induced liver injury.
Fifty C57BL/6 mice were randomly allocated into five groups: control, APAP model, AS-IV low-dose, AS-IV high-dose, and N-acetylcysteine treatment.
Serum AST and ALT levels were measured to evaluate liver function, and hepatic histopathological changes were assessed through HE staining.
RT-qPCR and Western blotting were used to quantify expression of key genes and proteins associated with the PPAR signaling pathway.
AS-IV treatment significantly reduced serum ALT and AST levels in AILI mice, indicating improved liver function.
Histopathological analysis showed AS-IV effectively alleviated liver damage.
AS-IV administration markedly increased expression levels of PCK1, RXRA, and PPARG, key regulators in the metabolic pathway.

Jiang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates astragaloside IV's protective effects on liver injury in mice, indicating potential therapeutic use.

This study aims to explore the protective mechanisms of astragaloside IV against acetaminophen-induced liver injury.
Fifty C57BL/6 mice were randomly allocated into five groups: control, APAP model, AS-IV low-dose, AS-IV high-dose, and N-acetylcysteine treatment.
Serum AST and ALT levels were measured to evaluate liver function, and hepatic histopathological changes were assessed through HE staining.
RT-qPCR and Western blotting were used to quantify expression of key genes and proteins associated with the PPAR signaling pathway.
AS-IV treatment significantly reduced serum ALT and AST levels in AILI mice, indicating improved liver function.
Histopathological analysis showed AS-IV effectively alleviated liver damage.
AS-IV administration markedly increased expression levels of PCK1, RXRA, and PPARG, key regulators in the metabolic pathway.

Jiang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark